Aclaris Therapeutics, Inc. ACRS
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -26.66% | -39.38% | -31.42% | 79.50% | -92.64% |
| Total Depreciation and Amortization | -9.09% | -6.14% | -20.31% | -28.67% | -38.55% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -18.28% | -34.87% | -16.61% | -96.24% | -22.19% |
| Change in Net Operating Assets | -1,421.73% | -287.22% | 16.02% | 425.55% | -97.61% |
| Cash from Operations | -120.27% | -98.61% | -39.00% | -46.91% | -149.69% |
| Capital Expenditure | 43.48% | -176.19% | 69.77% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -339.70% | 103.65% | -261.36% | 111.71% | 395.64% |
| Cash from Investing | -340.19% | 103.35% | -261.79% | 111.69% | 394.81% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -155.56% | 9.09% | 51.35% | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 53.37% | -- |
| Cash from Financing | 2,022.63% | 1,111.11% | 21,111.27% | -103.40% | -13,936.36% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 940.41% | -91.58% | 50.34% | 77.05% | -100.59% |